Merck & Cos Keytruda Gets Foot In The Door For FirstLine Gastric Cancer

Merck & Co’s Keytruda Gets Foot In The Door For First-Line Gastric Cancer

18:41 EDT 1 Jun 2019 | SCRIP

Results presented as ASCO from the mixed KEYNOTE-062 study suggest a place for pembrolizumab in first-line gastric cancer but data...